Literature DB >> 26177183

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.

Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma, Takeshi Johkoh, Fernando J Martinez, Jeffrey Myers, Shandra L Protzko, Luca Richeldi, David Rind, Moisés Selman, Arthur Theodore, Athol U Wells, Henk Hoogsteden, Holger J Schünemann.   

Abstract

BACKGROUND: This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.
METHODS: Systematic reviews and, when appropriate, meta-analyses were performed to summarize all available evidence pertinent to our questions. The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a multidisciplinary panel. Predetermined conflict-of-interest management strategies were applied, and recommendations were formulated, written, and graded exclusively by the nonconflicted panelists.
RESULTS: After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications to health equity, recommendations were made for or against specific treatment interventions.
CONCLUSIONS: The panel formulated and provided the rationale for recommendations in favor of or against treatment interventions for idiopathic pulmonary fibrosis.

Entities:  

Mesh:

Year:  2015        PMID: 26177183     DOI: 10.1164/rccm.201506-1063ST

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  513 in total

1.  Idiopathic pulmonary fibrosis a rare disease with severe bone fragility.

Authors:  Carla Caffarelli; Stefano Gonnelli; Maria Dea Tomai Pitinca; Valentina Francolini; Annalisa Fui; Elena Bargagli; Rosa Metella Refini; David Bennett; Ranuccio Nuti; Paola Rottoli
Journal:  Intern Emerg Med       Date:  2016-07-08       Impact factor: 3.397

2.  Eosinophilic pneumonia associated with pirfenidone therapy.

Authors:  Diana C Gomez; Borna Mehrad
Journal:  Eur Respir J       Date:  2016-07-07       Impact factor: 16.671

Review 3.  Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Authors:  Christopher L Mosher; Robert J Mentz
Journal:  Am Heart J       Date:  2020-05-06       Impact factor: 4.749

Review 4.  Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?

Authors:  Conal Hayton; Nazia Chaudhuri
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

5.  IPF lung fibroblasts have a senescent phenotype.

Authors:  Diana Álvarez; Nayra Cárdenes; Jacobo Sellarés; Marta Bueno; Catherine Corey; Vidya Sagar Hanumanthu; Yating Peng; Hannah D'Cunha; John Sembrat; Mehdi Nouraie; Swaroop Shanker; Chandler Caufield; Sruti Shiva; Mary Armanios; Ana L Mora; Mauricio Rojas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

6.  Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds.

Authors:  Kevin K Kim; Thomas H Sisson; Jeffrey C Horowitz
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

7.  p38 MAPK is Crucial for Wnt1- and LiCl-Induced Epithelial Mesenchymal Transition.

Authors:  Chun-Xiao Fang; Chun-Mei Ma; Ling Jiang; Xi-Ming Wang; Na Zhang; Ji-Na Ma; Tai-Hua Wu; Zhong-He Zhang; Guang-Dong Zhao; Ya-Dong Zhao
Journal:  Curr Med Sci       Date:  2018-06-22

8.  Comparing New-User Cohort Designs: The Example of Proton Pump Inhibitor Effectiveness in Idiopathic Pulmonary Fibrosis.

Authors:  Tanja Tran; Samy Suissa
Journal:  Am J Epidemiol       Date:  2021-05-04       Impact factor: 4.897

9.  HDAC8 inhibition ameliorates pulmonary fibrosis.

Authors:  Shigeki Saito; Yan Zhuang; Takayoshi Suzuki; Yosuke Ota; Marjorie E Bateman; Ala L Alkhatib; Gilbert F Morris; Joseph A Lasky
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

10.  BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis.

Authors:  Antje Prasse; Harald Binder; Jonas C Schupp; Gian Kayser; Elena Bargagli; Benedikt Jaeger; Moritz Hess; Susanne Rittinghausen; Louis Vuga; Heather Lynn; Shelia Violette; Birgit Jung; Karsten Quast; Bart Vanaudenaerde; Yan Xu; Jens M Hohlfeld; Norbert Krug; Jose D Herazo-Maya; Paola Rottoli; Wim A Wuyts; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2019-03-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.